The early-stage biotech company, focused on developing therapies
for rare diseases, has announced an asset purchase agreement with
Codexis, Inc. for the acquisition of Codexis' investigational
engineered enzymes that target Fabry and Pompe diseases.
CAMBRIDGE, Mass., July 10,
2024 /PRNewswire-PRWeb/ -- Crosswalk Therapeutics
(Crosswalk), a seed-stage biotech company focused on developing
therapies for rare diseases, has announced an asset purchase
agreement with Codexis, Inc. (NASDAQ: CDXS) for the
acquisition of Codexis' investigational engineered enzymes that
target Fabry and Pompe diseases. These assets will integrate into
Crosswalk's rapidly advancing R&D programs aimed at developing
best-in-class enzyme replacement therapies.
"Our Fabry and Pompe programs serve as the
cornerstone of our efforts in the lysosomal storage disease space –
and they're just the beginning of what we aim to achieve for the
broader rare disease community." – Madhu
Natarajan, CEO of Crosswalk Therapeutics
"Patients with lysosomal storage diseases often face burdensome
and frequent enzyme replacement infusions as part of current
therapeutic options. While these treatments save lives, they often
leave residual disease burden in tissues they don't reach, leading
to poor prognoses over time," says Rizwana
Islam, SVP and Head of Metabolism at Crosswalk.
Crosswalk's novel protein biodistribution platform offers a
plug-and-play solution for delivering engineered enzymes into
hard-to-reach tissues. The combination of these technologies into a
single construct potentially enables true best-in-class enzyme
replacement and marks the first milestone in Crosswalk's relentless
pursuit of functional cures. Convenient subcutaneous administration
will reduce the burden of therapy for patients, caregivers, and
families. Beyond initial efforts in Fabry and Pompe disease, the
Crosswalk platform has the capability to improve and expand
treatment options across a range of lysosomal storage diseases
including those with neurological manifestations such as
Metachromatic Leukodystrophy.
"Our Fabry and Pompe programs serve as the cornerstone of our
efforts in the lysosomal storage disease space – and they're just
the beginning of what we aim to achieve for the broader rare
disease community." says Madhu
Natarajan, CEO of Crosswalk Therapeutics.
About Crosswalk Therapeutics
Crosswalk Therapeutics (Crosswalk) is a seed stage biotech
company whose mission is to relentlessly pursue functional cures
for rare disease patients and their families. Crosswalk is
initially focused on rare diseases, with future plans to expand its
scope to include genetically defined common diseases. For more
information, visit:
https://www.linkedin.com/company/crosswalktx/.
Media Contact
Alan Clark, Crosswalk
Therapeutics, 1 857-600-0231, info@crosswalktx.com,
https://www.linkedin.com/company/crosswalktx/
View original
content:https://www.prweb.com/releases/crosswalk-therapeutics-announces-acquisition-of-rare-disease-assets-from-codexis-inc-302193196.html
SOURCE Crosswalk Therapeutics